Moreover, the median time to subsequent myeloma therapy was significantly lower for patients with CTLA4 rs231775 AA and AG genotype (36.3 months; 95% CI: 33.5-43) than in the patients with GG genotype (not reached; 95% CI 44.6-not reached) (p: 0.01). The gene discussed is CTLA4; the disease is plasma cell myeloma.